02.12.2020

AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.

more...

02.12.2020

Initiative BEAT-COV fordert UnterstĂĽtzung fĂĽr Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“

more...

18.08.2020

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

more...

17.08.2020

AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference

AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”

more...

09.06.2020

Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris

Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.

more...

05.06.2020

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)

more...

15.05.2020

AiCuris unterstützt das Land NRW bei der COVID-19 Ausbruchsbekämpfung in Schlachtbetrieben
An der Durchführung der ca. 20.000 Testung beteiligt sich AiCuris neben den vier Chemischen und Veterinäruntersuchungsämter des Landes.

more...

02.04.2020

AiCuris gets involved in the fight against Corona

“In times like these, biotech and pharmaceutical companies have a great societal responsibility”

more...

12.02.2020

AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir

AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

more...

12.11.2019

AiCuris Provides Corporate Update

AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.

more...

06.11.2019

AiCuris to Attend BIO-Europe® 2019 in Hamburg, Germany

Event provides a perfect partnering platform to exchange with industry executives and

more...

11.10.2019

AiCuris mit dem Wuppertaler Wirtschaftspreis ausgezeichnet
AiCuris Anti-infective Cures GmbH ist in der Kategorie „Unternehmen des Jahres“ mit dem Wuppertaler Wirtschaftspreis 2019 ausgezeichnet worden

more...

13.09.2019

Zum NDR-Bericht: AiCuris bleibt der Bekämpfung multiresistenter Bakterien treu
Zum NDR-Bericht:AiCuris bleibt der Bekämpfung multiresistenter Bakterien treu

more...

12.09.2019

Letermovir-Projekt von AiCuris wird Teil der Dauerausstellung im Deutschen Museum in MĂĽnchen
Als Preisträger enthüllten Prof. Dr. Helga Rübsamen-Schaeff, Gründungs-CEO, und Dr. Holger Zimmermann, CEO der AiCuris Anti-Infective Cures GmbH, das Modul gestern im Rahmen einer feierlichen Veranstaltung

more...

09.07.2019

AiCuris and Lysando join forces in the fight against antimicrobial resistance

Cooperation focused on the joint development and optimization of human anti-infective drug candidates against gram-negative and gram-positive bacteria in relevant indications using Lysando’s Artilysin®s technology platform

more...

14.05.2019

Prof. Dr. Helga Rübsamen-Schaeff erhält den Innovationspreis 2019 des Landes Nordrhein-Westfalen
Prof. Dr. Helga Rübsamen-Schaeff erhält den Innovationspreis 2019 des Landes Nordrhein-Westfalen

more...

04.04.2019

AiCuris to Present Clinical Data on AIC649 against Chronic Hepatitis B at the 2019 EASL meeting, the International Liver Congress
• Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

more...

19.03.2019

AiCuris plant sein weiteres Wachstum in Wuppertal
Unternehmen beabsichtigt Investitionen am Standort in Millionenhöhe

more...

11.03.2019

AiCuris nominated for “Deutscher Innovationspreis 2019”
AiCuris Anti-infective Cures GmbH is one of three companies nominated for the “Deutscher Innovationspreis 2019” in the category Medium-Sized Enterprises

more...

29.11.2018

AiCuris-Team receives German Future Prize 2018
Prof. Dr. Helga RĂĽbsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, were awarded the German Future Prize 2018

more...

28.11.2018

AiCuris-Team wins German Future Prize 2018
Prof. Dr. Helga RĂĽbsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH, were awarded the German Future Prize 2018

more...

01.10.2018

AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases

more...

12.09.2018

AiCuris-Team nominated for German Future Prize 2018
•AiCuris team nominated for their project, "Protection in the Absence of the Immune System - a Life-Saving Innovation against Dangerous Viruses"

more...

03.09.2018

AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B
Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups

more...

25.04.2018

Approval of MSD’s PREVYMIS™ (letermovir) in Japan triggers
In March the Japanese Ministry of Health, Labor and Welfare (MLHW) granted marketing authorization to MSD for PREVYMIS™ (letermovir)

more...

18.04.2018

AiCuris and Max Planck Institute of Molecular Physiology
AiCuris and the Max Planck Institute of Molecular Physiology (MPI) in Dortmund, Germany, have entered into a collaborative agreement to identify novel compounds for the treatment of viral and bacterial infections

more...

23.02.2018

AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany
AiCuris and MSD celebrate successful partnership in an exclusive media roundtable discussion pointing to the importance of pharma / biotech collaborations in drug development

more...

31.01.2018

Approval of MSD’s PREVYMIS™ (letermovir) by the European Commission triggers the next EUR 30 million milestone payment for AiCuris
EC approval allows for MSD to market this innovative product across Europe

more...

22.12.2017

ICIQ partners with German Biotech company AiCuris in a €750k project to train young scientists

more...

16.11.2017

New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance

more...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact us.